CSafe Global, a global provider of performance cold-chain solutions for the life sciences sector, announced it has appointed Sébastien Berrous as Director of Sales for France and Spain, where the company is rapidly expanding.
As part of a vigorous expansion drive which is seeing CSafe Global open new operational service centres around the world to support the rapidly growing needs of life science customers, Sébastien Berrous will be responsible for the company's overall business in France and Spain.
"Sébastien brings a wealth of medical sales leadership experience to our European team and will be instrumental in helping many of the top biopharmaceutical companies in Europe solve their most pressing high-risk cold chain challenges. His experience driving strategic market development excellence in senior roles at GE Healthcare and most recently at B. Braun, as France’s Managing Director of Inkospor branch, prepares Sebastien to best serve the market value priorities in France and Spain. We are very pleased to have Sebastien join the team and have every confidence in his market growth expertise as we continue to expand these important markets in Europe," says Nadine Siqueland, CSafe Vice President of Global Sales.
CSafe products protect temperature-sensitive biopharmaceutical products and provide life science companies with the necessary margin of safety when it comes to protecting medicines during their journey from producer to consumer. France is a major market for pharmaceuticals. It is Europe's fourth-largest producer, third-largest importer, fourth-largest exporter and second-largest consumer. Spain is Europe's fourth-largest pharma employer and sixth in terms of both production and consumption. Taken together the two countries constitute Europe's biggest concentration of pharma production.
Commenting on joining CSafe, Sebastien Berrous stated: "This is a very exciting time to be joining CSafe Global which stands out in the pharma-logistics sector as a dynamic, innovative and customer-centric company. I am looking forward to building on the successes already achieved and growing CSafe’s biopharmaceutical base in France and Spain."
![“Another key [UDI] benefit, because we're calling that product by the same name across the healthcare supply chain… rich and robust data that we can access around supply consumption and utilization rates. One of the buzz terms we've heard during the COVID-19 crisis was what's my burn rate? How fast am I going through gowns, masks, gloves?” – Mike Schiller, Senior Director at AHRMM](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2020/08/UDI.5f4d326e41d53.png?auto=format&fit=crop&h=146&w=340)
